Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Хронический вирусный гепатит D (ХВГD) у взрослых

Список литературы

  1. Инфекционные болезни: национальное руководство / под ред. Н. Д. Ющука, Ю. Я. Венгерова. - 3-е изд., перераб. и доп. - Москва: ГЭОТАР-Медиа, 2023. - 1104 с.
  2. Кожанова Т.В., Ильченко Л.Ю., Михайлов М.И. Гепатит дельта: этиология, клиника, диагностика, терапия. Архивъ внутренней медицины, 2014, 5: 21-8.
  3. Кожанова Т.В., Ильченко Л.Ю., Михайлов М.И. Вирусный гепатит дельта. Существует ли в Российской Федерации проблема дельта-инфекции? Экспериментальная и клиническая гастроэнтерология, 2014, 112: 4–12.
  4. Исаева О.В., Кюрегян К.К., Магомедова С.А., Михайлов М.И. Вирусный гепатит дельта: возможности терапии. Терапия. 2023, 9(3), 69–77.
  5. Negro F, Lok A. Hepatitis D: a review. JAMA. 2023 Dec 26;330(24):2376-2387. doi: 10.1001/jama.2023.23242.
  6. Asselah T, Rizzetto M. Hepatitis D virus infection. N Engl J Med. 2023 Jul 6;389(1):58-70. doi: 10.1056/NEJMra2212151.
  7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis delta virus. J Hepatol. 2023 Aug;79(2):433-460. doi: 10.1016/j.jhep.2023.05.001. Epub 2023 Jun 24.
  8. Buti M, Gonzalez A, Riveiro-Barciela M, Bourliere M. Management of chronic HBV-HDV patients chronic HBV-HDV infection: A review on new management options. United European Gastroenterol J. 2024 Mar;12(2):210-218. doi: 10.1002/ueg2.12494. Epub 2023 Dec 2.
  9. Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012, 1: e00049.
  10. Urban S., Bartenschlager R., Kubitz R., Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology, 2014, 147: 48-64.
  11. Blank A., Markert C., Hohmann N. et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol, 2016, 65: 483-9.
  12. Li W., Urban S. Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications. J Hepatol. 2016, 64(1 Suppl): S32-S40.
  13. Zhang Z, Urban S. New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies. J Hepatol. 2021 Mar; 74(3):686-699. DOI: 10.1016/j.jhep.2020.11.032
  14. Chen H, Shen D, Ji D, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019 Mar;68(3):512-521. doi: 10.1136/gutjnl-2018-316601. Epub 2018 Sep 18.
  15. Miao Z, Zhang S, Ou X, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020 Apr 27;221(10):1677-1687. doi: 10.1093/infdis/jiz633.
  16. Stockdale A, Kreuels B, Henrion M, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020, 73, 523–532.
  17. Вирусные гепатиты – достижения и новые перспективы. Материалы XII Всероссийской научно-практической конференции с международным участием, 19–20 сентября 2019 г. – Москва: ООО «Гепатит инфо», ООО «Медфорум», 2019. – 92 с.
  18. Абдурахманов Д.Т., Есмембетов К.И., Никулкина Е.Н. с соавт. Хронический гепатит дельта: современное состояние проблемы и перспективы лечения. Клиническая фармакология и терапия. 2019, 28: 26-34.
  19. Gish R, Wong R, Di Tanna G, et al. Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis. Hepatology. 2024 May 1;79(5):1129-1140. doi: 10.1097/HEP.0000000000000642. Epub 2023 Oct 23.
  20. Wranke A, Heidrich B, Deterding K, et al. Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection. Hepatol Int. 2023 Dec;17(6):1359-1367. doi: 10.1007/s12072-023-10575-0. Epub 2023 Oct 3.
  21. Kamal H, Westman G, Falconer K, et al. Long-term study of hepatitis delta virus infection at secondary care centers: the impact of viremia on liver-related outcomes. Hepatology. 2020 Oct;72(4):1177-1190. doi: 10.1002/hep.31214. Epub 2020 Sep 24.
  22. Fattovich G., Giustina G., Christensen E. et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut, 2000, 46: 420–6.
  23. Westbrook R., Dusheiko G. Natural history of hepatitis C. J Hepatol, 2014, 61: S58-68.
  24. Fernández-Montero J, Vispo E, Barreiro P, et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis. 2014 Jun;58(11):1549-53. doi: 10.1093/cid/ciu167. Epub 2014 Mar 14.
  25. Wei Y, et al. Comparison of modes of prothrombin time reporting in patients with advanced liver disease associated with viral hepatitis. J Thromb Thrombolysis. 2010, 29, 81-86.
  26. Wei Y. X. et al. Assessment of validity of INR system for patients with liver disease associated with viral hepatitis. J Thromb Thrombolysis. 2010, 30, 84-89.
  27. Клинические рекомендации «Рак печени (гепатоцеллюлярный)». https://cr.minzdrav.gov.ru/recomend/1_3.
  28. Romeo R. et al. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. PloS one. 2014, 9 (3), e92062.
  29. Tang J. R. et al. Clinical relevance of the detection of hepatitis delta virus RNA in serum by RNA hybridization and polymerase chain reaction. J Hepatol. 1994, 21 (6), 953-960.
  30. Yurdaydin C, Abbas Z, Buti M, et al. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. J Hepatol. 2019;70(5):1008-15. DOI: 10.1016/j.jhep.2018.12.022.
  31. Bazinet M. et al. Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139‐Ca and pegylated interferon therapy in chronic hepatitis B virus/hepatitis delta virus coinfection. Hepatol Commun. 2021, 5 (2), 189-202.
  32. Le Gal F. et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol. 2005, 43 (5), 2363-2369.
  33. Castelnau C. et al. Efficacy of peginterferon alpha‐2b in chronic hepatitis delta: relevance of quantitative RT‐PCR for follow‐up. Hepatology. 2006, 44 (3), 728-735.
  34. Schaper M. et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol. 2010, 52 (5), 658-664.
  35. Deutsch M. et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology. 1997, 26 (1), 206-210.
  36. Kuzu F., Akdemir E. Subacute thyroiditis during peginterferon alfa therapy for chronic hepatitis delta. Euras J Med Oncol. 2018, 2 (3), 182-185.
  37. Bogomolov P., Alexandrov A., Voronkova N. et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol. 2016, 65: 490-8.
  38. Богомолов П.О., Ивашкин В.Т., Буеверов А.О., и др. Эффективность и безопасность булевиртида в лечении хронического гепатита D – результаты рандомизированных контролируемых исследований. Инфекционные болезни. 2020, 18: 153-62. doi: 10.20953/1729-9225-2020-4-153-162.
  39. Богомолов П.О., Ивашкин В.Т., Буеверов А.О., и др. Эффективность и безопасность противовирусной терапии у пациентов с компенсированным циррозом печени HDV-этиологии. Терапевтический архив, 2021, 93: 1290-9.
  40. Магомедова С.А., Абдурахманов Д.Т., Арбулиева Е.А. Опыт монотерапии булевиртидом у пациентов с циррозом печени HDV-этиологии в Республике Дагестан. Инфекционные болезни. 2022; 20(2): 112-116.
  41. Жданов К.В., Гусев Д.А., Романова С.Ю. с соавт. Эффективность и безопасность булевиртида в лечении хронического гепатита D – опыт реальной практики в Санкт-Петербурге. Инфекционные болезни. 2023; 21(1): 64-69.
  42. Богомолов П.О., Буеверов А.О., Барсукова Н.А. с соавт. Лечение пациентов с хронической HDV-инфекцией – опыт реальной клинической практики в Московской области. Инфекционные болезни. 2023; 21(2): 5-14.
  43. Магомедова С.А., Абдурахманов Д.Т., Арбулиева Е.А. Опыт противовирусной терапии хронического гепатита D у пациентов с циррозом и нарушениями функции печени. Инфекционные болезни. 2023; 21(2): 15-20.
  44. Атмурзаева Д.Т., Иванова М.Р. Опыт противовирусной терапии хронического гепатита D в Кабардино-Балкарской Республике. Инфекционные болезни. 2023; 21(1): 59-63.
  45. Рымаренко Н.В., Ачкасова Т.А. Противовирусная терапия хронического гепатита D в Республике Крым – опыт реальной практики. Инфекционные болезни. 2023; 21(4): 34-38.
  46. Слепцова С.С., Илларионова Н.А., Слепцов С.С. с соавт. Опыт противовирусной терапии хронического гепатита D в Республике Саха (Якутия). Инфекционные болезни. 2024; 22(1): 11–16.
  47. Бахтина В.А., Запашняя О.В., Поникарева Е.К. Лечение хронического гепатита D в Краснодарском крае – опыт реальной практики. Инфекционные болезни. 2024, 22(2), 22–30.
  48. Wedemeyer H, Schöneweis K, Bogomolov P, et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet Infect Dis. 2023 Jan;23(1):117-129. doi: 10.1016/S1473-3099(22)00318-8.
  49. Wedemeyer H, Aleman S, Brunetto MR, et al; MYR 301 Study Group. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med. 2023 Jul 6;389(1):22-32. doi: 10.1056/NEJMoa2213429. Epub 2023 Jun 22.
  50. Wedemeyer H, Aleman S, Brunetto M, et al. Bulevirtide monotherapy in patients with chronic HDV: efficacy and safety results through week 96 from a phase 3 randomized trial. J Hepatol. 2024 May 9:S0168-8278(24)00333-7. doi: 10.1016/j.jhep.2024.05.001. Epub ahead of print.
  51. Lampertico P, Wedemeyer H, Brunetto M, et al. Continued treatment of early non-responder or partial virologic responders with bulevirtide monotherapy in patients with chronic hepatitis D through week 96 leads to improvement in virologic and biochemical responses. J Hepatol. 2023, 78, suppl. 1, S113-4, LBP20.
  52. De Ledinghen V., Asselah T., Roulot D. et al. et al. Treatment with bulevirtide, with or without peg-interferon, in HDV infected patients in a real-life setting. Two-year results from the French multicenter early access program. Hepatology. 2022, 76: S26-S28. Available at https://www.natap.org/2022/AASLD/AASLD_80.htm.
  53. Degasperi E, de Lédinghen V, Reiberger T, et al. Virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with bulevirtide monotherapy: the retrospective multicenter European study (Save-D). J Hepatol. 2023, 78, suppl. 1, S107, LBP-11.
  54. Degasperi E, Anolli M, Jachs M, et al. Long-term virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with bulevirtide monotherapy for up to 120 weeks: a retrospective multicenter european study (Save-D). J Hepatol. 2024, 80, S793-S794, WED-391. doi: 10.1016/S0168-8278(24)02203-7.
  55. Lampertico P, Aleman S, Brunetto M, et al. Efficacy and safety of 144 weeks of bulevirtide 2 mg or 10 mg monotherapy from the ongoing phase 3 study, MYR301. J Hepatol. 2024, 80, S92, LBP-029. doi: 10.1016/S0168-8278(24)00596-8.
  56. Anolli MP, Degasperi E, Allweiss L, et al. A 3-year course of bulevirtide monotherapy may cure HDV infection in cirrhotics. J Hepatol. 2023 Jan 3:S0168-8278(22)03475-4. doi: 10.1016/j.jhep.2022.12.023.
  57. Asselah T, Chulanov V, Lampertico P, et al. Bulevirtide combined with pegylated interferon for chronic hepatitis D. N Engl J Med. 2024 Jun 6. doi: 10.1056/NEJMoa2314134. Epub ahead of print.
  58. Wedemeyer H., Yurdaydìn C., Dalekos et al. HIDIT Study Group. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med, 2011, 364: 322-31.
  59. Heidrich B., Yurdaydın C., Kabaçam G. et al. HIDIT-1 Study Group. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014, 60: 87-97.
  60. Wedemeyer H., Yurdaydin C., Hardtke S. et al. HIDIT-II study team. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis. 2019, 19: 275-86.
  61. Bremer B., Anastasiou O., Hardtke S. et al. Residual low HDV viremia is associated with HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis D (delta): results from the HIDIT-II study. J Hepatol. 2020, 73, suppl. 1: S868.
  62. Asselah T, Chulanov V, Lampertico P, et al. 48-week off-therapy efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: final results from the phase 2b, open-label, randomised, multicentre study MYR204. J Hepatol. 2024, 80, S1-S2. GS-002. doi:10.1016/S0168-8278(24)00425-2.
  63. Zoulim F, Chulanov V, Lampertico P, et al. Undetectable HDV RNA at 24 weeks of treatment with combination therapy is an important predictor of maintained response off-therapy. J Hepatol. 2024, 80, S764. FRI-371. doi:10.1016/S0168-8278(24)02136-6.
  64. Zoulim F, Asselah T, Chulanov V, et al. Undetectable hepatitis delta virus RNA at the end of treatment with bulevirtide and pegylated interferon alpha-2a is an important predictor of 48 weeks sustained virologic response in chronic hepatitis delta. J Hepatol. 2024, 80, S796, WED-395. doi:10.1016/S0168-8278(24)02207-4.
  65. Dietz-Fricke C, Tacke F, Zöllner C, et al. Treating hepatitis D with bulevirtide - Real-world experience from 114 patients. JHEP Rep. 2023 Mar 15;5(4):100686. doi: 10.1016/j.jhepr.2023.100686.
  66. Allweiss L, Volmari A, Suri V, et al. Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies. J Hepatol. 2024 Jun;80(6):882-891. doi: 10.1016/j.jhep.2024.01.035. Epub 2024 Feb 8.
  67. Lampertico P, Aleman S, Bogomolov P, et al. Improvement in liver histology is observed in most patients with chronic hepatitis delta after 48 weeks of bulevirtide monotherapy. J Hepatol. 2024, 80, S794, WED-392. doi: 10.1016/S0168-8278(24)02204-9.
  68. Lampertico P, Brunetto M, Buti M, et al. Impact of bulevirtide given with or without nucleos (t)ide analogues on 48-week virologic outcomes in patients with chronic hepatitis delta virus infection. J Hepatol. 2024, 80, S758, TOP-400. doi:10.1016/S0168-8278(24)02124-X.
  69. Aleman S, Wedemeyer H, Brunetto M, et al. High rates of adherence to bulevirtide monotherapy for chronic hepatitis delta through 96 weeks: results from an interim analysis of the phase 3 study MYR301. Gastroenterology. 2024, 166, S-1603, Sa1626. doi:10.1016/S0016-5085(24)04142-8.
  70. Buti M., Wedemeyer H., Aleman S., et al. Treatment with bulevirtide improves patient reported outcomes in patients with chronic hepatitis delta (CHD): an exploratory analysis of a phase 3 trial at 48 weeks. J Hepatol., 2022, 77, suppl.1: S103, OS149.
  71. Dietz-Fricke C, Degasperi E, Jachs M, et al. Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case series. Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000847. Epub ahead of print.
  72. Sandmann L, Berg T, Deterding K, et al. Antiviral therapy of chronic hepatitis D virus infection - Addendum to the S3 guideline "Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection" of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS). Z Gastroenterol. 2023 Dec;61(12):e715-e732. doi: 10.1055/a-2181-3345. Epub 2023 Dec 11.
  73. Bogomolov P, Bueverov A, Barsukova N, et al. Bulevirtide in patients with non-compensated liver cirrhosis due to hepatitis D. Hepatology. 2023, The Liver Meeting, Boston, Massachusetts, Nov 10-14, 2023, S2142, Abstract 1259-C. Available at https://www.natap.org/2023/AASLD/AASLD_18.htm
  74. Begré L. et al. Long-term trends of alanine aminotransferase levels among persons living with human immunodeficiency virus/hepatitis B virus with and without hepatitis delta coinfection. Frontiers in medicine. 2022, 9, 988356.
  75. Buti M. et al. Clinical outcome of acute and chronic hepatitis delta over time: a long‐term follow‐up study. J Viral Hepat. 2011, 18 (6), 434-442.
  76. Kalkan Ç. et al. Non‐invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta. J Viral Hepat. 2023, 30 (5), 406-416.
  77. Yang A. H. et al. Shear wave elastography: How well does it perform in chronic hepatitis D virus infection? J Viral Hepat. 2022, 29 (12), 1127-1133.
  78. Инструкция по медицинскому применению лекарственного препарата Пегасис, регистрационный номер П N013704/01, https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=abc8c083-5b49-4fcc-892b-16dc99051722.
  79. Инструкция по медицинскому применению лекарственного препарата Пегальтевир регистрационный номер ЛП-002542, https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3e2b22dd-60df-4316-ab5c-3876edaeda33.
  80. Инструкция по медицинскому применению лекарственного препарата Пэгинтерферон альфа-2b, регистрационный номер ЛП-003437, https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=a750cc86-a205-46d6-ba7c-2d74cf446883.
  81. De Ledinghen V., Zoulim F. et al. Treatment with bulevirtide, with or without PEG-interferon, in HIVHBV/HDV co-infected patients in a real-life setting.
  82. J Hepatol. 2023, 78, suppl. 1, S1161, SAT-185.
  83. Comandini U. et al. “Real world” efficacy of bulevirtide in HBV/HDV-related cirrhosis including people living with HIV: results from the compassionate use programme at INMI Spallanzani in Rome, Italy. HIV Med. 2023, 24: 1075-82.
  84. Ambrosioni J, Levi L, Alagaratnam J, et al; EACS Governing Board. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Med. 2023 Nov;24(11):1126-1136. doi: 10.1111/hiv.13542. Epub 2023 Oct 18.
  85. NICE (National Institute of Care end Excellence). Bulevirtide for treating chronic hepatitis D. Technology appraisal guidance. Published 07 June 2023. Available at https://www.nice.org.uk/guidance/ta896.
  86. World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. 2024, 272 p. Available at https://www.who.int/publications/i/item/9789240090903.
  87. Castera L, Lampertico P, Bogomolov P, et al. Improvement in noninvasive tests (LSM, FIB-4, and APRI) is seen through 96 weeks of bulevirtide monotherapy in CHD regardless of virologic response. Hepatology. 2023;78:S572-4.
  88. Manhas S., Han B., Xu S., Urban S. et al. Bulevirtide is broadly active against all HDV genotypes expressing envelopes from HBV genotypes A-H and a large panel of clinical isolates. J Hepatol., 2022, 77, suppl.1: S244, THU302.
  89. Mateo R., Aeschbacher T., Liu Y. et al. Polymorphic analysis of bulevirtide sequence in PreS1 of large HBsAg across HBV genotypes A-H. J Hepatol. 2022, 77, suppl.1: S247, THU309.
  90. Aleman S, Liu Y, Xu S, et al. No detectable resistance to bulevirtide monotherapy through 96 weeks treatment in patients with chronic hepatitis D. Hepatology. 2023;78:S398-9.
  91. Jachs M, Panzer M, Hartl L, et al. Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression. JHEP Rep. 2023 Apr 7;5(8):100751. doi: 10.1016/j.jhepr.2023.100751.
  92. Jachs M, Schwarz C, Panzer M, et al. Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study. Aliment Pharmacol Ther. 2022 Jul;56(1):144-154. doi: 10.1111/apt.16945. Epub 2022 May 5.
  93. Scheller L., Hilgard G., Anastasiou O. et al. Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients. Medicine (Baltimore), 2021, 100: e26571.
  94. Barreira Díaz A, Rando A, Feliu-Prius A, et al. LINK-B: study protocol of a retrospective and prospective project for identification and linkage to care of people living with hepatitis B in a large health area of Barcelona. BMJ Open. 2022 Dec 23;12(12):e062680. doi: 10.1136/bmjopen-2022-062680.
  95. Kim RG, McDonell C, McKinney J, et al. Staff-facilitated telemedicine care delivery for treatment of hepatitis c infection among people who inject drugs. Healthcare (Basel). 2024 Mar 25;12(7):715. doi: 10.3390/healthcare12070715.
  96. Rosato V, Nevola R, Conturso V, et al. Telemedicine improves HCV elimination among italian people who use drugs: an innovative therapeutic model to increase the adherence to treatment into addiction care centers evaluated before and during the COVID-19 pandemic. Biology (Basel). 2022 May 24;11(6):800. doi: 10.3390/biology11060800.
  97. Исаева О.В., Кожанова Т. В., Ильченко Л. Ю. с соавт. Влияние вакцинации против гепатита В на распространенность гепатита дельта в эндемичном регионе. Инфекционные болезни: новости, мнения, обучение. 2019, 8: 36-42.
  98. Goyal A., Murray J. The impact of vaccination and antiviral therapy on hepatitis B and hepatitis D epidemiology. PLoS ONE, 2014, 9: e110143.
  99. Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep. 2020 Jul 3;69(5):1-38. doi: 10.15585/mmwr.rr6905a1.
  100. Vanwolleghem T, Armstrong PA, Buti M, et al. The elimination of hepatitis D as a public health problem: needs and challenges. J Viral Hepat. 2024 Jan;31(1):47-50.
  101. Meszaros M, Hilleret M, Dumortier J, et al. Bulevirtide efficacy and safety in chronic hepatitis delta patients on liver transplant waiting list. J Hepatol. 2024, 80, S802, FRI-3

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*